Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$24.3 million.

  • Aligos Therapeutics' Free Cash Flow fell 2111.34% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.2 million, marking a year-over-year increase of 686.72%. This contributed to the annual value of -$80.9 million for FY2024, which is 235.02% down from last year.
  • According to the latest figures from Q3 2025, Aligos Therapeutics' Free Cash Flow is -$24.3 million, which was down 2111.34% from -$15.5 million recorded in Q2 2025.
  • Over the past 5 years, Aligos Therapeutics' Free Cash Flow peaked at -$13.6 million during Q2 2023, and registered a low of -$37.8 million during Q4 2021.
  • Over the past 5 years, Aligos Therapeutics' median Free Cash Flow value was -$20.9 million (recorded in 2022), while the average stood at -$22.0 million.
  • In the last 5 years, Aligos Therapeutics' Free Cash Flow soared by 5537.87% in 2022 and then plummeted by 4316.25% in 2024.
  • Aligos Therapeutics' Free Cash Flow (Quarter) stood at -$37.8 million in 2021, then skyrocketed by 55.38% to -$16.9 million in 2022, then tumbled by 34.28% to -$22.7 million in 2023, then grew by 18.78% to -$18.4 million in 2024, then plummeted by 32.29% to -$24.3 million in 2025.
  • Its Free Cash Flow was -$24.3 million in Q3 2025, compared to -$15.5 million in Q2 2025 and -$20.9 million in Q1 2025.